Clinical Trial: A Single-center, Interventional Diagnostic Study With Minimal Risks and Constraints, Aimed at Longitudinally Evaluating Serum Antibody Levels in Patients With COVID-19 According to the Severity of Their Symptoms.

U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT06862531) titled 'A Single-center, Interventional Diagnostic Study With Minimal Risks and Constraints, Aimed at Longitudinally Evaluating Serum Antibody Levels in Patients With COVID-19 According to the Severity of Their Symptoms.' on March 05.

Brief Summary: The COVERT protocol was designed to assess, through a longitudinal analysis, the level of antibodies present in the serum of patients with COVID-19, the duration and the persistence of the humoral response in correlation with the severity of the disease.

Study Start Date: Sept. 25, 2020

Study Type: INTERVENTIONAL

Condition: COVID-19

Intervention: BIOLOGICAL: blood sample

A sample of blood...